MX392972B - Metodo para utilizar ciclodextrina. - Google Patents

Metodo para utilizar ciclodextrina.

Info

Publication number
MX392972B
MX392972B MX2020000205A MX2020000205A MX392972B MX 392972 B MX392972 B MX 392972B MX 2020000205 A MX2020000205 A MX 2020000205A MX 2020000205 A MX2020000205 A MX 2020000205A MX 392972 B MX392972 B MX 392972B
Authority
MX
Mexico
Prior art keywords
cellular
cyclodextrin
diabetes
cholesterol
relating
Prior art date
Application number
MX2020000205A
Other languages
English (en)
Spanish (es)
Other versions
MX2020000205A (es
Inventor
Alessia Fornoni
Gomez Sandra Merscher
Original Assignee
L&F Res Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by L&F Res Llc filed Critical L&F Res Llc
Publication of MX2020000205A publication Critical patent/MX2020000205A/es
Publication of MX392972B publication Critical patent/MX392972B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2020000205A 2012-04-13 2013-04-12 Metodo para utilizar ciclodextrina. MX392972B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261624087P 2012-04-13 2012-04-13
PCT/US2013/036484 WO2013155485A2 (en) 2012-04-13 2013-04-12 Method of using cyclodextrin

Publications (2)

Publication Number Publication Date
MX2020000205A MX2020000205A (es) 2022-06-06
MX392972B true MX392972B (es) 2025-03-21

Family

ID=49328287

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020000205A MX392972B (es) 2012-04-13 2013-04-12 Metodo para utilizar ciclodextrina.
MX2014012200A MX371073B (es) 2012-04-13 2013-04-12 Método para utilizar ciclodextrina.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2014012200A MX371073B (es) 2012-04-13 2013-04-12 Método para utilizar ciclodextrina.

Country Status (8)

Country Link
US (4) US10195227B2 (https=)
EP (2) EP2836221B1 (https=)
JP (4) JP6491089B2 (https=)
CN (2) CN104244956B (https=)
CA (1) CA2870316C (https=)
ES (1) ES2959119T3 (https=)
MX (2) MX392972B (https=)
WO (1) WO2013155485A2 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104244956B (zh) * 2012-04-13 2020-04-17 L&F研究有限公司 使用环糊精的方法
CA2905788C (en) 2013-03-12 2022-08-16 Emily A. Stein Dental composition comprising chelator and base
JP6418911B2 (ja) * 2014-11-18 2018-11-07 学校法人中部大学 Ｇｌｐ−１分泌促進剤
CA2988529A1 (en) 2015-06-10 2016-12-15 Vtesse, Inc. Hydroxypropyl beta-cyclodextrin compositions and methods
CN105395549A (zh) * 2015-11-03 2016-03-16 天津医科大学总医院 烟酸的新用途
CN109982718A (zh) * 2016-09-19 2019-07-05 阿托恩波罗斯生命科学 基于环糊精的聚合物、方法、组合物及其应用
WO2018075622A1 (en) * 2016-10-19 2018-04-26 University Of Miami Materials and methods for modulating insulin signaling and preserving podocyte function
CN107982546A (zh) * 2017-12-05 2018-05-04 中国药科大学 基于主客体相互作用的酸敏感超分子纳米粒及其应用
US11925659B2 (en) 2018-10-29 2024-03-12 Cyclo Therapeutics, Inc. Methods for treating Alzheimer's disease
JP7607935B2 (ja) 2019-01-03 2025-01-06 サイクラリティ・セラピューティクス・インコーポレイテッド シクロデキストリン二量体、それらの組成物、及びそれらの使用
WO2020213010A1 (en) * 2019-04-16 2020-10-22 Celagenex Research (India) Pvt. Ltd. Synergistic lipid controlling compositions
EP4058570A4 (en) * 2019-11-11 2023-12-27 Atsuo Ochi METHOD AND KIT FOR REPROGRAMMING SOMATIC CELLS
US12226431B2 (en) 2021-09-11 2025-02-18 Porosome Therapeutics, Inc. Aerosol and topical administration of a formulation containing cyclodextrin, quercetin and zinc, in combination or separately, to mitigate infection by enveloped viruses
CA3189915A1 (en) * 2020-08-27 2022-03-03 Diana KERWIN Methods for the treatment of cardiovascular disease with cyclodextrins
IL300881A (en) * 2020-08-27 2023-04-01 Beren Therapeutics P B C Methods for preventing embolization of cholesterol crystals with cyclodextrins
KR20230096975A (ko) * 2020-08-27 2023-06-30 베렌 테라퓨틱스 피.비.씨. 사이클로덱스트린을 이용한 콜레스테롤 결정 색전증 치료 방법
CN112089843B (zh) * 2020-10-13 2022-11-04 合肥工业大学 一种抗心力衰竭的联用组合药物及其在制备抗心力衰竭药物中的应用
AU2022222756A1 (en) * 2021-02-18 2023-09-14 Beren Therapeutics P.B.C. Methods for the treatment of familial heterozygous and homozygous hypercholesterolemia with cyclodextrins
CN113295793B (zh) * 2021-05-20 2022-11-04 复旦大学附属中山医院 预测早期糖尿病以及糖尿病发生的生物标志物、其检测方法与应用
US20240238327A1 (en) * 2021-09-01 2024-07-18 Renatus Inc. Pharmaceutical composition comprising gamma-cyclodextrin polymer and uses thereof
WO2023156966A1 (en) 2022-02-18 2023-08-24 Beren Therapeutics P.B.C. Compositions of hydroxypropyl-beta-cyclodextrin and methods of purifying the same

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0672100B2 (ja) * 1989-11-15 1994-09-14 株式会社上野製薬応用研究所 利尿剤
US5840713A (en) * 1995-04-03 1998-11-24 Weisz; Paul B. Therapy for tissue membrane insufficiency
CA2348292A1 (en) 1998-10-30 2000-05-11 Takeda Chemical Industries, Ltd. Betacellulin protein-containing preparation
US6756504B2 (en) * 2000-04-19 2004-06-29 Yissum Research Development Company Of The Hebrew University Of Jerusalem Sphingolipids
US20040121983A1 (en) * 2002-08-12 2004-06-24 Council Of Scientific And Industrial Research Method for treating leishmaniasis using methyl-beta-cyclodextrin
ES2457017T3 (es) 2002-08-19 2014-04-24 Soho Flordis International Pty Ltd Composiciones que comprenden formadores de complejos con la grasa de la dieta y procedimientos para su uso
JP2004323443A (ja) * 2003-04-25 2004-11-18 Tokai Univ 抗血栓薬
WO2005000217A2 (en) * 2003-06-06 2005-01-06 Merck & Co., Inc. Combination therapy for the treatment of dyslipidemia
US9200245B2 (en) 2003-06-26 2015-12-01 Seng Enterprises Ltd. Multiwell plate
US7393826B2 (en) * 2003-07-03 2008-07-01 Lipid Sciences, Inc. Methods and apparatus for creating particle derivatives of HDL with reduced lipid content
US7276351B2 (en) 2003-09-10 2007-10-02 Seahorse Bioscience Method and device for measuring multiple physiological properties of cells
US20050129677A1 (en) * 2003-12-10 2005-06-16 Shengwen Li Lipid rafts and clostridial toxins
CN1282425C (zh) * 2004-06-22 2006-11-01 王美岭 苹果醋营养品及其生产方法
US20060128653A1 (en) 2004-12-10 2006-06-15 Chunlin Tang Pharmaceutical formulation of decitabine
JP2006191830A (ja) * 2005-01-12 2006-07-27 Unitika Ltd 脂肪の蓄積を抑制する食品
CA2595606C (en) * 2005-01-27 2014-12-16 Erimos Pharmaceuticals Llc Oral formulations for delivery of catecholic butanes including ndga compounds
WO2007056435A2 (en) 2005-11-08 2007-05-18 The General Hospital Corporation Dynamin mediated diseases and associated methods and products
US20090324624A1 (en) * 2006-06-16 2009-12-31 Florida Atlantic University Chitin micro-particles as an adjuvant
EP1894924A1 (en) * 2006-08-29 2008-03-05 Phenex Pharmaceuticals AG Heterocyclic FXR binding compounds
MY150649A (en) * 2006-10-20 2014-02-14 Icos Corp Compositions of chk1 inhibitors
EP1920785A1 (en) 2006-11-07 2008-05-14 Boehringer Ingelheim Vetmedica Gmbh Liquid preparation comprising a complex of pimobendan and cyclodextrin
WO2010042202A1 (en) 2008-10-07 2010-04-15 Fibrogen, Inc. Methods for treatment of podocyte injury
CN102438614A (zh) * 2008-10-10 2012-05-02 利默里克生物制药公司 用于治疗的吡喃酮类似物
US8202702B2 (en) 2008-10-14 2012-06-19 Seahorse Bioscience Method and device for measuring extracellular acidification and oxygen consumption rate with higher precision
US8263413B1 (en) 2008-10-17 2012-09-11 Andrew S Hansen Methods for analyzing lipids and membrane proteins in biological matter using stable isotopes and mass spectrometry
EP2352502A4 (en) 2008-11-06 2012-12-26 Univ Miami LIMITED PROTEOLYSIS OF CD2AP AND PROGRESSION OF NURSE DISEASE
WO2010103823A1 (ja) 2009-03-12 2010-09-16 パナソニック株式会社 画像表示装置および画像表示方法
JP5847721B2 (ja) * 2009-10-08 2016-01-27 ソン、ホ、バイオメッド、カンパニー、リミテッドＳｏｎｇ Ｈｏ Ｂｉｏｍｅｄ Ｃｏ．， Ｌｔｄ 高水溶性２−ヒドロキシプロピル−ベータシクロデキストリンを有効成分として含有する、肥満疾患の予防および治療用組成物
US20120251527A1 (en) 2009-11-06 2012-10-04 University Of Miami Podocyte specific assays and uses thereof
US8372877B2 (en) * 2010-04-16 2013-02-12 Cumberland Pharmaceuticals Stabilized statin formulations
EP2595623B1 (en) 2010-07-19 2018-02-28 The U.S.A. as represented by the Secretary, Department of Health and Human Services Use of delta tocopherol for the treatment of lysosomal storage disorders
US10052345B2 (en) 2010-10-19 2018-08-21 University Of Miami Assays, methods and kits for predicting renal disease and personalized treatment strategies
CN104244956B (zh) * 2012-04-13 2020-04-17 L&F研究有限公司 使用环糊精的方法

Also Published As

Publication number Publication date
EP4299121A3 (en) 2024-07-24
MX371073B (es) 2020-01-15
ES2959119T3 (es) 2024-02-20
EP2836221A4 (en) 2016-07-27
CN111419870A (zh) 2020-07-17
US20190262385A1 (en) 2019-08-29
CN104244956B (zh) 2020-04-17
JP2018203747A (ja) 2018-12-27
EP2836221B1 (en) 2023-07-05
CN104244956A (zh) 2014-12-24
MX2014012200A (es) 2015-06-17
JP6491089B2 (ja) 2019-03-27
US20150065457A1 (en) 2015-03-05
US20210228616A1 (en) 2021-07-29
EP2836221A2 (en) 2015-02-18
MX2020000205A (es) 2022-06-06
JP2023178518A (ja) 2023-12-15
CA2870316A1 (en) 2013-10-17
JP2021155436A (ja) 2021-10-07
WO2013155485A3 (en) 2013-12-19
CA2870316C (en) 2022-04-19
US10980828B2 (en) 2021-04-20
US20230338412A1 (en) 2023-10-26
WO2013155485A2 (en) 2013-10-17
US10195227B2 (en) 2019-02-05
JP2015512949A (ja) 2015-04-30
EP4299121A2 (en) 2024-01-03

Similar Documents

Publication Publication Date Title
MX392972B (es) Metodo para utilizar ciclodextrina.
MX2014010481A (es) Nuevas composiciones para el tratamiento de la esclerosis lateral amiotrofica.
MX346428B (es) Metodo para tratar eccema.
BR112015003004A2 (pt) análogos de piridazina , 1-4 dissubstituída e métodos para tratar condições relacionadas com deficiência de smn
WO2012093809A3 (en) New bicyclic compound for modulating g protein-coupled receptors
EA201491386A1 (ru) Соединения, ингибирующие металлоферменты
EP2672967A4 (en) COMPOUNDS AND METHODS FOR KINASE MODULATION AND INDICATING THEREFOR
PH12014502704B1 (en) Compounds and compositions for modulating egfr activity
DK3287142T3 (da) Fremgangsmåder til behandling af tilstande, som er forbundet med masp-2-afhængig komplementaktivering
BR112013023306A2 (pt) métodos para tratar pelo menos uma parte de uma formação subterrânea
BR112013007604A2 (pt) “composto, composição, método para controlar um nematoide parasitário e semente tratada”
WO2013003601A9 (en) Method for treating phytophotodermatitis
UY4153Q (es) Batería
BR112013016241A2 (pt) composto, e, método para fabricar um composto
BR112013018945A2 (pt) processo para a preparação de 4-amino-5-fluoro-3-halo-6-(substituído)picolinatos.
BR112015013152A2 (pt) composição para tratamento de uma formação subterrânea , método para tratar uma formação subterrânea , e método para reduzir a viscosidade de óleo cru.
BR112013019798A2 (pt) composições bakuchiol para tratamento de hiperpigmentação pós-inflamatória.
BR112015002493A2 (pt) composto , composição farmacêutica , método para o tratamento do câncer , processo para a preparação de uma composição farmacêutica , conjunto , utilização de um composto e invenção.
EA201390616A1 (ru) ЛЕЧЕНИЕ НАРУШЕНИЙ, АССОЦИИРОВАННЫХ С ГЕНОМ MeCP2
MX371378B (es) Moduladores mejoradores de la actividad de hec1 y metodos para los mismos.
UY33976A (es) Derivados de pirazolo-pirimidina.
EP2862936A4 (en) Oxidoreductase reaction control and use thereof
MX2015007778A (es) Prediccion de bioactivacion molecular.
UY4152Q (es) Batería
EA201390876A1 (ru) Соединения, ингибирующие металлоферменты